{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:03:24Z","timestamp":1774933404626,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-017-0802-4","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T07:12:40Z","timestamp":1515741160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Treating C3 glomerulopathy with eculizumab"],"prefix":"10.1186","volume":"19","author":[{"given":"Thomas","family":"Welte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kappes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Seidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"H\u00e4ffner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Walz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5893-4293","authenticated-orcid":false,"given":"Elke","family":"Neumann-Haefelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"issue":"12","key":"802_CR1","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMra1108178","volume":"366","author":"S Sethi","year":"2012","unstructured":"Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med. 2012;366(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"802_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/ki.2011.399","volume":"81","author":"S Sethi","year":"2012","unstructured":"Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012;81(5):434\u201341.","journal-title":"Kidney Int"},{"issue":"11","key":"802_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nrneph.2012.213","volume":"8","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012;8(11):634\u201342.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"802_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079\u201389.","journal-title":"Kidney Int"},{"key":"802_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","volume":"71","author":"P Iatropoulos","year":"2016","unstructured":"Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016;71:131\u201342.","journal-title":"Mol Immunol"},{"issue":"1","key":"802_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","volume":"9","author":"NR Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014;9(1):46\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"802_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s004670050768","volume":"14","author":"SD Marks","year":"2000","unstructured":"Marks SD, Rees L. Spontaneous clinical improvement in dense deposit disease. Pediatr Nephrol. 2000;14(4):322\u20134.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"802_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00467-011-2059-7","volume":"27","author":"DF Lu","year":"2012","unstructured":"Lu DF, Moon M, Lanning LD, McCarthy AM, Smith RJ. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol. 2012;27(5):773\u201381.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"802_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2215\/CJN.03480708","volume":"4","author":"SH Nasr","year":"2009","unstructured":"Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol. 2009;4(1):22\u201332.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"802_CR10","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454\u201364.","journal-title":"Kidney Int"},{"key":"802_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12882-015-0219-x","volume":"17","author":"S Alasfar","year":"2016","unstructured":"Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. BMC Nephrol. 2016;17:7.","journal-title":"BMC Nephrol"},{"issue":"5","key":"802_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1681\/ASN.2013070715","volume":"25","author":"L Zand","year":"2014","unstructured":"Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, Smith RJ, Sethi S. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol. 2014;25(5):1110\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"802_CR13","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/ndt\/gfs430","volume":"28","author":"TD Barbour","year":"2013","unstructured":"Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant. 2013;28(7):1685\u201393.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"802_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1055\/s-0034-1375701","volume":"40","author":"S Sethi","year":"2014","unstructured":"Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost. 2014;40(4):416\u201321.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"802_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MNH.0b013e328345848b","volume":"20","author":"M Pickering","year":"2011","unstructured":"Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens. 2011;20(3):271\u20137.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"802_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2215\/CJN.07110810","volume":"6","author":"S Sethi","year":"2011","unstructured":"Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, Cramer C, Nester CM, Smith RJ. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol. 2011;6(5):1009\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1\u20132","key":"802_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2010.12.020","volume":"365","author":"LT Roumenina","year":"2011","unstructured":"Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365(1\u20132):8\u201326.","journal-title":"J Immunol Methods"},{"issue":"14","key":"802_CR18","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.molimm.2011.04.005","volume":"48","author":"RJ Smith","year":"2011","unstructured":"Smith RJ, Harris CL, Pickering MC. Dense deposit disease. Mol Immunol. 2011;48(14):1604\u201310.","journal-title":"Mol Immunol"},{"issue":"3","key":"802_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference. Kidney Int. 2017;91(3):539\u201351.","journal-title":"Kidney Int"},{"issue":"5","key":"802_CR20","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1681\/ASN.2005010078","volume":"16","author":"GB Appel","year":"2005","unstructured":"Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005;16(5):1392\u2013403.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"802_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5414\/CN107945","volume":"83","author":"P Giaime","year":"2015","unstructured":"Giaime P, Daniel L, Burtey S. Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy. Clin Nephrol. 2015;83(1):57\u201360.","journal-title":"Clin Nephrol"},{"issue":"4","key":"802_CR22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/j.1600-6143.2011.03923.x","volume":"12","author":"JA McCaughan","year":"2012","unstructured":"McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant. 2012;12(4):1046\u201351.","journal-title":"Am J Transplant"},{"issue":"5","key":"802_CR23","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/ki.2015.227","volume":"88","author":"C Rabasco","year":"2015","unstructured":"Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernandez-Juarez G, Gonzalez F, Avila A, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015;88(5):1153\u201360.","journal-title":"Kidney Int"},{"issue":"1","key":"802_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.ki.5000269","volume":"70","author":"C Licht","year":"2006","unstructured":"Licht C, Heinen S, Jozsi M, Loschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, et al. Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 2006;70(1):42\u201350.","journal-title":"Kidney Int"},{"issue":"11","key":"802_CR25","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00467-015-3111-9","volume":"30","author":"K Haffner","year":"2015","unstructured":"Haffner K, Michelfelder S, Pohl M. Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression. Pediatr Nephrol. 2015;30(11):1951\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"802_CR26","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMc1112273","volume":"366","author":"E Daina","year":"2012","unstructured":"Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med. 2012;366(12):1161\u20133.","journal-title":"N Engl J Med"},{"issue":"12","key":"802_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMc1111953","volume":"366","author":"M Vivarelli","year":"2012","unstructured":"Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med. 2012;366(12):1163\u20135.","journal-title":"N Engl J Med"},{"issue":"5","key":"802_CR28","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2215\/CJN.12901211","volume":"7","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012;7(5):748\u201356.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"802_CR29","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s00467-013-2503-y","volume":"28","author":"S Gurkan","year":"2013","unstructured":"Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol. 2013;28(10):1975\u201381.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"802_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40620-013-0008-1","volume":"27","author":"N Besbas","year":"2014","unstructured":"Besbas N, Gulhan B, Gucer S, Korkmaz E, Ozaltin F. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J Nephrol. 2014;27(4):457\u201360.","journal-title":"J Nephrol"},{"issue":"6","key":"802_CR31","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00467-013-2711-5","volume":"29","author":"C Rousset-Rouviere","year":"2014","unstructured":"Rousset-Rouviere C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol. 2014;29(6):1107\u201311.","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"802_CR32","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s00467-013-2565-x","volume":"28","author":"E Kerns","year":"2013","unstructured":"Kerns E, Rozansky D, Troxell ML. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy. Pediatr Nephrol. 2013;28(11):2227\u201331.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"802_CR33","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00467-013-2748-5","volume":"29","author":"O Ozkaya","year":"2014","unstructured":"Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol. 2014;29(7):1283\u20137.","journal-title":"Pediatr Nephrol"},{"key":"802_CR34","first-page":"201568","volume":"2014","author":"A Berthe-Aucejo","year":"2014","unstructured":"Berthe-Aucejo A, Sacquepee M, Fila M, Peuchmaur M, Perrier-Cornet E, Fremeaux-Bacchi V, Deschenes G. Blockade of alternative complement pathway in dense deposit disease. Case Rep Nephrol. 2014;2014:201568.","journal-title":"Case Rep Nephrol"},{"issue":"10","key":"802_CR35","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00467-014-2839-y","volume":"29","author":"A Sanchez-Moreno","year":"2014","unstructured":"Sanchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, Lopez-Trascasa M, Bedoya R, Rodriguez de Cordoba S, Ybot-Gonzalez P. Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol. 2014;29(10):2055\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"802_CR36","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2215\/CJN.01360215","volume":"10","author":"MJ Oosterveld","year":"2015","unstructured":"Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, et al. Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol. 2015;10(10):1773\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"802_CR37","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","volume":"65","author":"M Le Quintrec","year":"2015","unstructured":"Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, Goujon JM, Fremeaux-Bacchi V, Fakhouri F. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis. 2015;65(3):484\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"802_CR38","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00467-015-3306-0","volume":"31","author":"CL Tran","year":"2016","unstructured":"Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, Smith RJ, Fervenza FC. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatr Nephrol. 2016;31(4):683\u20137.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"802_CR39","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00467-017-3619-2","volume":"32","author":"C Lebreton","year":"2017","unstructured":"Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-Bacchi V, Sellier-Leclerc AL. C3 glomerulopathy and eculizumab: a report on four paediatric cases. Pediatr Nephrol. 2017;32(6):1023\u20138.","journal-title":"Pediatr Nephrol"},{"issue":"23","key":"802_CR40","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med"},{"issue":"7","key":"802_CR41","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s00467-005-1858-0","volume":"20","author":"K Haffner","year":"2005","unstructured":"Haffner K, Zimmerhackl LB, von Schnakenburg C, Brandis M, Pohl M. Complete remission of post-transplant FSGS recurrence by long-term plasmapheresis. Pediatr Nephrol. 2005;20(7):994\u20137.","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"802_CR42","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256\u201364.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"802_CR43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00467-015-3061-2","volume":"30","author":"A Payette","year":"2015","unstructured":"Payette A, Patey N, Dragon-Durey MA, Fremeaux-Bacchi V, Le Deist F, Lapeyraque AL. A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol. 2015;30(6):1033\u20137.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"802_CR44","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4049\/jimmunol.1302288","volume":"192","author":"M Ramadass","year":"2014","unstructured":"Ramadass M, Ghebrehiwet B, Smith RJ, Kew RR. Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies. J Immunol. 2014;192(3):1220\u201330.","journal-title":"J Immunol"},{"issue":"7","key":"802_CR45","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1681\/ASN.2011121186","volume":"23","author":"LC Herlitz","year":"2012","unstructured":"Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D'Agati VD. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol. 2012;23(7):1229\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"802_CR46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4103\/0971-4065.134089","volume":"24","author":"S Thomas","year":"2014","unstructured":"Thomas S, Ranganathan D, Francis L, Madhan K, John GT. Current concepts in C3 glomerulopathy. Indian J Nephrol. 2014;24(6):339\u201348.","journal-title":"Indian J Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-017-0802-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T19:10:54Z","timestamp":1547233854000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-017-0802-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1186\/s12882-017-0802-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"31 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients gave written informed consent for eculizumab treatment. The study was approved by the Ethics Committee of the University Medical Center, Freiburg, Germany (reference number #400\/16).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GW and CB have received honoraria for participating in Alexion Pharmaceuticals advisory board meetings. Alexion Pharmaceuticals was not involved in drafting, editing or publication of this study. CB is an employee of Bioscientia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"7"}}